SYNERGETIC EFFECTS OF THYMOQUINONE +VIT C + VIT D IN ONCOLOGY NUTRITION
Technical field and problem
The invention relates to oncology nutrition compositions comprising thymoquinone (TQ), vitamin C (ascorbic acid), and vitamin D (preferably cholecalciferol or calcitriol) intended as adjuncts to cancer therapy and supportive care. The problem addressed is to provide a nutraceutical /medical nutrition formulation that:
- Targets multiple hallmarks of cancer (proliferation, survival, angiogenesis, metastasis, immune evasion)
- Modulates oxidative stress and tumor microenvironment in a dose- and context-dependent way
- Enhances chemoprevention and improves tolerance/efficacy of standard chemo and radiotherapy while suitable for oral nutrition support.
Direct anticancer mechanisms
Key, repeatedly reported actions of thymoquinone (from Nigella sativa) include:
- Inhibition of proliferation and induction of apoptosis in diverse cancer cell lines via modulation of PI3K/AKT, mTOR, NFκB, and related pathways.oncotarget+3
- Down regulation of prosurvival and proinflammatory mediators such as NFκB, TNFα signaling, COX2, and antiapoptotic proteins (Bcl2 family), leading to caspase activation.
- Suppression of EMT, migration, and invasion through inhibition of TWIST1, FAK, ERK phosphorylation, and secretion of MMP2/9, reducing metastatic potential
- Interference with cancer stemness and cell cycle progression (e.g., p21 upregulation, CDK modulation) depending on model.
- Disrupts PI3K/AKT signaling, limits growth factor receptor pathways (EGFR, VEGFR2) and reduces metastatic markers (e.g., MMP2, CD44
- Exhibits dose- and timedependent cytotoxicity in leukemia (K562) cells, indicating broad-spectrum antitumor potential
Antioxidant and redox modulation
- TQ scavenges superoxide and nitric oxide and induces expression of antioxidant enzymes (catalase, superoxide dismutase, glutathione peroxidase, glutathioneStransferases, glutathione reductase
- This dual antioxidant/prooxidant potential can attenuate tumorigenic oxidative stress while still promoting apoptosis in cancer cells under specific conditions.
Immunomodulatory and microenvironment effects
- TQ suppresses TNFα–induced NFκB activation by inhibiting IκBα kinase activation, IκBα phosphorylation/degradation, and p65 nuclear translocation
- By modulating NFκB and cytokine signaling, TQ can reduce chronic inflammation associated with carcinogenesis and potentially improve antitumor immune responses.
These mechanistic features make TQ a rational core of an oncology nutrition formulation aiming at multitargeted modulation of tumor biology and host response.
Vitamin C: oncologic mechanisms and nutritional role
In an oncology nutrition product, vitamin C can be positioned at nutritional-to-moderately supranutritional
doses for antioxidant, immune, and microenvironment modulation, while synergizing with TQ’s
redoxmodulating and antiinflammatory actions.
doses for antioxidant, immune, and microenvironment modulation, while synergizing with TQ’s
redoxmodulating and antiinflammatory actions.
Dosedependent dual role in cancer
- At physiological (nutritional) concentrations (≈50–200 µM), vitamin C functions as a ROSscavenging antioxidant, reducing oxidative DNA damage and maintaining genomic stability, thus exerting chemopreventive effects.
- At high pharmacologic (often intravenous) doses, vitamin C can act as a prooxidant in the tumor milieu, generating hydrogen peroxide and ROS, leading to DNA damage, ATP depletion, and degradation of HIF1α in cancer cells.
Selective toxicity to cancer cells
- Oxidized vitamin C (dehydroascorbic acid, DHA) is transported into cancer cells via upregulated GLUT1, then reduced intracellularly, consuming glutathione and generating oxidative stress; this mechanism contributes to selective tumor cell killing.
- High-dose vitamin C–induced ROS activates PARP and depletes NAD⁺, inhibiting glycolysis in glycolysisaddicted cancer cells, thereby exerting cytotoxic effects.
Modulation of hypoxia and angiogenesis
- In tumorbearing mouse models, increased intratumoral ascorbate depresses HIF1 transcriptional activity, reduces microvessel density and hypoxic regions, and slows tumor growth, indicating an effect on hypoxiadriven signaling and angiogenesis.
Nutritional and supportive aspects
- Vitamin C supports collagen synthesis, wound healing, immunity, and antioxidant defense, which are critical in malnourished or treatmentstressed oncology patients.pmc.ncbi.nlm.nih+1
- Dietary vitamin C supplementation has been associated with improved outcomes in some breast cancer cohorts, suggesting benefit as part of nutritional support.
Vitamin D: anticancer and immunonutritional mechanisms
Anticancer and chemopreventive effects
- Active vitamin D (1,25dihydroxyvitamin D₃) exerts antiproliferative, prodifferentiation, and proapoptotic actions through the vitamin D receptor (VDR), influencing cell cycle regulators (e.g., p21, p27) and proapoptotic genes.
- In colon carcinogenesis models, vitamin D₃ supplementation reduces tumor number and modulates Wnt/βcateninrelated markers such as DKK1, TGFβ signaling,
Synergy with thymoquinone in colon cancer models
- In an AOMinduced colon cancer rat model, the combination of vitamin D and TQ significantly lowered tumor count and tumor/colon surface area ratio compared to each monotherapy or unsupplemented groups.
- Combined Vit D/TQ treatment yielded the lowest number of large aberrant crypt foci, reduced glandular dysplasia, and better preservation of colonic mucosal architecture, indicating enhanced chemoprevention.
Modulation of PI3K/AKT/mTOR and response to chemotherapy
- In colon cancer cells, triple therapy with vitamin D₃, thymoquinone, and 5fluorouracil enhanced antitumorigenic effects via attenuation of the PI3K/AKT/mTOR signaling pathway
- This demonstrates that vitamin D and TQ together can potentiate standard chemotherapy and modulate survival pathways, suggesting similar benefit when used as a nutritional adjuvant in patients under treatment.
Immunomodulation and systemic relevance
- Vitamin D has welldocumented roles in modulating innate and adaptive immunity, reducing chronic inflammation and possibly improving responses to infections and treatmentrelated complications in oncology patients.
Synergistic rationale: TQ + vitamin C + vitamin D in oncology nutrition
While direct data for “TQ + vitamin C + vitamin D” as a triple nutraceutical combination are limited, the published bipartite synergies
(TQ+Vit D, Vit C+chemo, Vit D+chemo, TQ+chemo) and overlapping mechanistic targets strongly support
the inventive concept of a trinutrient oncology nutrition product.
(TQ+Vit D, Vit C+chemo, Vit D+chemo, TQ+chemo) and overlapping mechanistic targets strongly support
the inventive concept of a trinutrient oncology nutrition product.
Complementary targeting of cancer hallmarks
- TQ primarily targets proliferation, survival, inflammation, EMT, metastasis, and angiogenesis via PI3K/AKT, NFκB, mTOR, EGFR/VEGFR2, MMPs, and EMT transcription factors
- Vitamin C mainly influences redox balance, DNA damage/repair, hypoxia (HIF1), and tumor vasculature while supporting systemic antioxidant status.pmc.ncbi.nlm.nih+2
- Vitamin D modulates proliferation, differentiation, apoptosis, and Wnt/TGFβ/Smad signaling and has demonstrated chemopreventive synergy with TQ in colon cancer models and in combination with chemotherapy.
Redox and signaling crosstalk
- TQ and vitamin C both modulate ROS; TQ upregulates endogenous antioxidant enzymes while vitamin C directly scavenges ROS and, at higher concentrations, induces controlled oxidative stress in cancer cells.
- Vitamin D and TQ together downregulate PI3K/AKT/mTOR signaling, as demonstrated in colon cancer cells and animal models, and vitamin C–mediated HIF1α suppression can further attenuate survival pathways and angiogenesis.
Microenvironment, inflammation, and immunity
- TQ inhibits NFκB and TNFα signaling and reduces proinflammatory mediators; vitamin C and D likewise reduce inflammation and support immune function, including effects on cytokine profiles and immune cell differentiation.oncotarget+4
- Vitamin C–driven reduction of tumor hypoxia and microvessel density, combined with TQ/Vit D–mediated suppression of angiogenic and metastatic pathways, may normalize tumor vasculature and improve nutrient/oxygen distribution.
Evidence for combination/adjunct strategies
- TQ augmented the chemopreventive effect of Vit D in colon carcinogenesis, lowering tumor number and severity beyond either monotherapy.
- Triple combination of vitamin D₃, TQ, and 5FU showed enhanced tumoricidal effects through PI3K/AKT/mTOR attenuation, outperforming single or dual therapies in colon cancer cell models.
Proposed mechanisms of action for the patented composition
In the patent application, you can synthesize the above into a mechanistic framework like:
Multipathway inhibition of tumor growth and survival
TQ and Vit D cooperatively inhibit PI3K/AKT/mTOR, Wnt/βcatenin, and NFκB signaling, leading to reduced proliferation, increased apoptosis, and decreased survival in malignant cells.
Redox homeostasis and selective oxidative stress
The formulation supplies antioxidant defense via TQinduced enzymes and Vit C scavenging, protecting normal tissues, while in tumor cells the interplay of high local oxidative stress, DHA transport, and TQ’s proapoptotic signaling induces selective oxidative damage and metabolic crisis.
Modulation of tumor hypoxia, angiogenesis, and EMT
Vitamin C reduces HIF1 activity and tumor microvessel density; TQ suppresses VEGFR2 and angiogenic signaling and inhibits EMT, migration, and invasion; Vit D supports normalization of epithelial architecture and reduces preneoplastic lesions, particularly in colon.
Antiinflammatory and immunomodulatory actions
The combination reduces proinflammatory cytokine signaling (TNFα, NFκB), enhances antitumor immune surveillance, and potentially mitigates treatmentinduced systemic inflammation and fatigue.oncotarget
Nutritional support and treatment tolerance
Vitamin C and D correct common deficiencies in oncology patients, supporting bone health, immune competence, antioxidant status, and overall nutritional repletion, while TQ provides additional cytoprotective antioxidant and antiinflammatory benefits to normal tissues
Suggested experimental data package
Even if not all data are yet generated, you can describe planned or exemplary studies:
In vitro studies
- Cancer cell lines: colorectal (e.g., HT29, HCT116), breast, leukemia (K562), and others.sciencedirect+3
- Treatment groups: control, TQ alone, Vit C alone, Vit D alone, TQ+Vit D, TQ+Vit C, Vit C+Vit D, TQ+Vit C+Vit D.
- Outcomes: cell viability (MTT/XTT), apoptosis (Annexin V/PI), caspase activation, ROS levels, mitochondrial potential, expression of PI3K/AKT/mTOR, NFκB, HIF1α, VEGF, EMT markers (Ecadherin, vimentin, TWIST1), MMP2/9, DKK1, p21, TGFβ/Smad.
In vivo chemoprevention models
- AOMinduced colon carcinogenesis in rodents with dietary supplementation of the threecomponent formulation, endpoints: tumor incidence and multiplicity, large ACF count, histopathological grading, mucosal architecture, molecular markers as above.
- Optionally, xenograft models to test combination with standard chemotherapy (e.g., 5FU) and measure tumor growth curves, survival, systemic toxicity markers, and microvessel density.
Pilot clinical/observational data in oncology nutrition
- Small openlabel or observational study in patients receiving chemotherapy or radiotherapy, giving the TQ+Vit C+Vit D nutrition formula.
- Endpoints: quality of life, fatigue scores, inflammatory markers (CRP, IL6), oxidative stress biomarkers, immune cell subsets, treatment tolerance (dose reductions, delays), and exploratory tumor response metrics.
Positioning within oncology nutrition
- The composition is designed as an oral nutrition supplement (powder, capsule, or liquid) for cancer patients as an adjunct to standard of care, not as a standalone chemotherapy.
- It targets welldocumented deficiencies (Vit D, Vit C) and adds a phytochemical (TQ) with strong preclinical anticancer evidence and low toxicity as reported in multiple studies.
RESEARCH DONE BY ABINSHA SHAJU (RESEARCH HEAD- ZEED DROPS RESEARCH LABORATORIES UAE ) AND TEAM.